Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Self-reported symptoms in healthy young adults to predict potential coronavirus disease 2019

Maya Nitecki1, Boris Taran1, Itay Ketko1,2, Gil Geva1, Roey Yosef3, Itay Toledo3, Glad Twig1,4,5, Eva Avramovitch1,6, Barak Gordon1, Estela Derazne5, Noam Fink1, Ariel Furer1,4,5,*

1) Israel Defense Force Medical Corps, Tel Hashomer, Ramat Gan, Israel
2) Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer, Israel
3) Israel Defense Force Computer and IT Directorate, Tel Hashomer, Ramat Gan, Israel
4) Department of Military Medicine, Hebrew University, Jerusalem, Israel
5) Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
6) Department of Management, Bar-Ilan University, Israel

Objective: To assess the utility of self-reported symptoms in identifying positive coronavirus disease 2019 (COVID-19) cases among predominantly healthy young adults in a military setting.

Methods: A questionnaire regarding COVID-19 symptoms and exposure history was administered to all individuals contacting the Israeli Defence Forces Corona call-centre, before PCR testing. Surveyed symptoms included cough, fever, sore throat, rhinorrhoea, loss of taste or smell, chest pain and gastrointestinal symptoms. Factors were compared between positive and negative cases based on confirmatory test results, and positive likelihood ratios (LR) were calculated. Results were stratified by sex, body mass index, previous medical history and dates of questioning, and a multivariable analysis for association with positive test was conducted.

Results: Of 24 362 respondents, 59.1% were men with a median age of 20.5 years (interquartile range 19.6–22.4 years). Significant positive LRs were associated with loss of taste or smell (LR 3.38, 95% CI 3.01–3.79), suspected exposure (LR 1.33, 95% CI 1.28–1.39) and fever (LR 1.26, 95% CI 1.17–1.36). Those factors were also associated with positive PCR result in a multivariable analysis (OR 3.51, 95% CI 3.04–4.06; OR 1.86, 95% CI 1.65–2.09; and OR 1.34, 95% CI 1.19–1.51, respectively). Reports of loss of taste or smell increased gradually over time and were significantly more frequent during the late period of the study (63/5231, 1.21%; 156/7941, 1.96%; and 1505/11 190, 13.45%; p < 0.001).

Conclusion: Loss of taste or smell, report of a suspicious exposure and fever (>37.5°C) were consistently associated with positive LRs for a positive SARS-CoV-2 PCR test result, in a population of predominantly young and healthy adults.

© 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Eligibility for COVID-19 testing by the ICC, including those with suspicious exposure history. We included all individuals who were deemed referred soldiers for swab tests based on report of symptoms and at least two acute respiratory symptoms (cough, shortness of breath, fever >38°C); or (b) one symptom combined with a suspicious exposure; or (c) loss of taste or smell as a sole symptom.

Materials and methods

Study population

The special IDF COVID-19 centre (ICC) handled documentation of all individuals with suspicious symptoms, those quarantined, and all confirmed COVID-19 cases. This included collection of data obtained through contact tracing and enquiry hotline. ICC referred soldiers for swab tests based on report of symptoms and exposure history. We included all individuals who were deemed eligible for COVID-19 testing by the ICC, including those voluntarily calling to report symptoms or a suspected exposure, or those actively addressed following an epidemiological investigation. Eligibility for confirmatory testing was directed by the surgeon general and approved by public health officers on a case-by-case basis. Testing was approved for those with: (a) presence of at least two acute respiratory symptoms (cough, shortness of breath, sore throat, fever >38°C); or (b) one symptom combined with a suspicious exposure; or (c) loss of taste or smell as a sole symptom.

Primary outcome

The primary outcome measure was the positive likelihood ratio (LR) of symptoms suggesting a positive real-time reverse transcript (rRT-) PCR result.

Data collection

Answers to questions asked by the ICC before swab testing were drawn from a digital database where each individual has a unique identification number. Symptoms surveyed included: cough, fever (>37.5°C), sore throat, rhinorrhea, loss of taste or smell, chest pain and gastrointestinal symptoms (GI, i.e. abdominal pain, vomiting, or diarrhoea). Suspected exposure was defined as close contact with a confirmed COVID-19 patient or recent (<14 days) international travel (for questionnaire example see Supplementary material, Appendix S2). Data were collected between 26 March and 2 August 2020. A group of 6643 individuals had COVID-19 tests without answering the questionnaires so their symptoms and exposure history data were unavailable and they were excluded from the study. PCR test results were merged using the identification number from a digital laboratory database and classified as either positive or negative. For positive cases, only the first positive test was included, and data were collected only from the questionnaire obtained before this test. The following covariates were abstracted from the medical registry: body mass index (BMI), baseline health and comorbidities, as detailed in the Supplementary material (Appendix S1).

Viral RNA test

Viral RNA presence was examined using rRT-PCR based on the SARS-CoV-2 Centers for Disease Control and Prevention (CDC) protocol [20]; using viral markers for each of the three viral genes (RdRP, N gene and E gene). Cycle threshold values were reported, as well as an internal control marker. A threshold of 40 cycles and below was considered positive. Results in which only N gene was present within the range of 36–40 cycles, were defined as marginally positive. In those cases, a certified physician and a public-health officer interpreted the result according to the clinical context, and the individual was re-tested if deemed necessary. Additional details on testing methods are available elsewhere [21].

All swab materials were processed in the central IDF laboratory, throughout the entire study.

Statistical analysis

Prevalence of each reported symptom and exposure were compared between positive and negative rRT-PCR groups. Continuous variables were presented as medians and interquartile ranges, and categorical variables were presented as percentages and counts. Positive LR, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 95% CI for test statistics were calculated using the methods of Simel et al. [22] and Wilson [23]. Results were stratified by sex, BMI category, previous medical history and dates of questioning. Univariate and multivariable logistic regression models were performed to assess the relationship between a positive PCR test result (dependent variable) and clinical (asthma, chronic sinusitis, hypertension and BMI), anamnestic (report of symptoms and exposure) and demographic factors (sex and age – analysed as continuous variable and as categorical ≤20; 21–22; ≥23) as independent variables. Six statistically significant independent variables were included in multivariable analysis and selected using forward stepwise method (p-in 0.05; p-out 0.10). No collinearity was found among independent variables included in multivariable analysis, maximum variance inflation factor = 1.039. Odds ratios (OR), 95% CI and p values are presented.

To assess trends in symptom distribution over time, we selected three consequent periods to represent different phases of the pandemic: the initial COVID-19 outbreak, mitigation of disease spread and the increased disease burden following the reopening of communities, as shown in Fig. 2b. For each symptom, analysis of...
variance was used to compare the proportion of individuals reporting its presence between periods. As no homogeneity of variances was found, multiple comparisons were made with post hoc Dunnett T3 test.

Values of p that were <0.05 and CI exclusive of the null were considered statistically significant. Statistical analyses were conducted using Microsoft Excel (version 2013; Microsoft, Redmond, WA, USA) and IBM SPSS Statistics for Windows (version 25.0; IBM, Armonk, NY, USA).

The institutional review board of the IDF approved this study (protocol number 2082-2020), and waived the requirement for written informed consent based on preserving participants’ anonymity.

Results

Overall, 31,155 individuals were identified between 26 March and 2 August 2020. We excluded those with no recorded result, or results processed in an external laboratory (n = 150) and individuals with missing questionnaire items (n = 6643, 21.4%) (Fig. 1, see Supplementary material, Table S1, for comparison with the included cohort). Ultimately, 24,362 respondents were included in the analysis. Over half (59.1%) were men, with a median age of 20.5 years (interquartile range 19.6–22.4 years) of whom 65% (n = 15,534) had unimpaired health at baseline. Of all PCR tests, 5.5% (n = 1338) were positive, 5.7% in men and 5.2% in women. During the first, second and third periods of the study, a total of 5231, 7941 and 11,190 tests were conducted with 2.25% (n = 118), 2.29% (n = 182) and 9.27% (n = 1038) positivity rates, respectively. Characteristics of the study population are shown in Table 1.

Reported symptoms

Cough was the most commonly reported symptom (13,675/24,362, 56.1%), followed by report of suspected exposure (12,211/24,362, 50.1%) and fever (6896/24,362, 28.3%). The item with highest sensitivity (65.5% (63-68.1%)) was suspected exposure, followed by cough (55.5% (52.9-58.2%)) and fever (35.1% (32.6-37.7%)). Highest specificity was seen with GI symptoms (98.6% (98.5-98.8%)), followed by chest pain (98.2% (98.1-98.4%)) and loss of taste or smell (93.7% (93.4-94.1%)). Loss of taste or smell was also found to have the highest PPV (16.4% (14.8-17.9%)). Suspected
exposure was found to have the highest NPV (96.2% [95.9–96.5%]) followed by loss of taste or smell (95.3% [95.2–95.5%]) and fever (95% [94.8–95.2%]). The overall distribution of reports on surveyed factors, sensitivity, specificity, PPV and NPV, are summarized in Table 2.

Comparing the distribution of reports over time (Fig. 2a, see Supplementary material, Tables S2 and S3) demonstrated that suspected exposure decreased between first and second periods (2303/5231 (44.0%), 2411/7941 (30.4%), respectively, p < 0.001), and was significantly higher during the third period (7498/11 190 (67.0%), p < 0.001). The same trend was seen with reports of cough (2747/5231 (52.5%), 3591/7941 (45.2%), 7337/11 190 (65.6%), p < 0.001) and fever (1705/5231 (26.2%), 1927/7941 (24.3%), 3598/11 190 (32.2%, p 0.038, p < 0.001). For loss of taste or smell, a significant gradual increase in reporting during the three study periods occurred (63/5231 (1.2%), 156/7941 (1.9%), 1505/11 190 (13.5%), all p < 0.001). For context, disease burden in Israel during this timeline decreased between the first and second periods and increased drastically in the third period (Fig. 2b).

**Likelihood ratio**

Of symptoms surveyed, loss of taste or smell had the highest positive LR (LR 11.25, 95% CI 6.28–20.9) and disease severity [27,28]. Varying definitions of fever between studies, and different survey components (where in some body temperature was not a mandatory question) also contribute to unequivocal findings. In the current study, fever >37.5°C was second and third periods, the positive LR for loss of taste or smell decreased substantially but remained significant (LR 2.62, 95% CI 2.36–5.05, LR 2.05, 95% CI 1.83–2.31, respectively) (Table 3). Fever was also found to have significant positive LR (LR 1.4, 95% CI 1.2–1.3) during the third period whereas exposure shown significant positive LR in both earlier periods but not in the third, accompanied by lower specificity in the latest period (see Supplementary material, Table S2).

In a multivariable logistic regression loss of taste or smell (OR 3.51, 95% CI 3.04–4.06), fever (OR 1.34, 95% CI 1.19–1.51) and history of exposure (OR 1.86, 95% CI 1.65–2.09) were the only factors independently associated with a positive test (see Supplementary material, Table S10).

**Discussion**

In order to make better use of limited COVID-19 confirmatory tests and identify those at highest risk for infection, in Israel, like in many other countries, certain criteria were used to determine testing eligibility [24–26]. In this study, suspicious exposure, loss of taste or smell and fever were associated with a COVID-19 molecular diagnosis in over 24 000 young adults, suggesting that self-reported symptoms are an effective way to triage testing in this population.

Previous reports have been inconsistent with respect to the association between fever and a positive test [11–13]. These conflicting data may stem from the inclusion of populations with a variety of age groups, a factor shown to affect clinical manifestation and disease severity [27,28]. Varying definitions of fever between studies, and different survey components (where in some body temperature was not a mandatory question) also contribute to unequivocal findings. In the current study, fever >37.5°C was
significantly associated with COVID-19 diagnosis. Yet, when three consequent periods were compared, fever had significant positive LR only in the late period. This could represent lack of power in earlier periods due to smaller participant numbers, or a true increase in fever as a manifestation of disease. Nonetheless, given the high likelihood observed we suggest prioritizing febrile or subfebrile individuals for testing, especially if they are young and healthy at baseline. This recommendation should be taken with caution as the specificity of fever was 72% in our study and we hypothesize that with upsurge in seasonal cold and flu during wintertime this will decrease.

Our results suggest that exposure was associated with disease only in earlier periods and not in the latest one. When considering the nationwide disease burden, it is evident that by the third period infection was widespread and much more prevalent. Hence, stricter enforcement perhaps resulted in many of these contacts being less endangering in the latest period. Based on our findings and the relatively low specificity of 51%, it is reasonable to refine the definition of an exposure to achieve better specificity in these circumstances.

In general, we found symptom reporting to be time dependent and mostly parallel to disease propagation in the country [3]. This trend was notable among positive cases but also within the entire cohort, implying a possible behavioural component. The phenomenon of healthy concerned individuals seeking medical attention was demonstrated previously in the setting of different catastrophic events and natural disasters [29], and our findings suggest similar behaviour during the COVID-19 pandemic. Notably, reporting of loss of taste or smell, increased over time, resulting in a decline in the magnitude of the positive LR. Among possible explanations is the increased media coverage and public recognition of this complaint as suggestive of COVID-19. Previously an opposite phenomenon was reported, where with mounting media reports of loss of smell the association between this complaint and a positive test increased [13]. The increase in loss of taste or smell in our cohort could have been attributed to an increase in prevalence of a different illness manifesting with these symptoms, but it is highly unlikely that this could explain a nine-fold increase within a month. Nonetheless, loss of taste or smell remains significantly and consistently associated with a positive likelihood for COVID-19, and fair PPV, despite the possible reporting bias. As this is a specific complaint [30] reaching as high as 94% in our cohort, unlike other flu-like symptoms, we suggest that young individuals presenting with loss of taste or smell should be prioritized for testing. In contrast to previous reports [11,13] we did not find respiratory symptoms to be associated with a positive test.

Our study includes a unique cohort comprised mainly of young healthy adults, a subgroup that has been overlooked in previous reports [11–13] but is the most common disease transmitting

| Table 3 |

| Suspected Exposure | LR Period 1 (26 March to 30 April 2020) | LR Period 2 (1 May to 30 June 2020) | LR Period 3 (1 July to 2 August 2020) |
|--------------------|----------------------------------------|------------------------------------|----------------------------------------|
| GI symptoms        | 1.98 (0.27–14.5)                       | 0.44 (0.06–3.14)                   | 0.93 (0.59–1.49)                      |
| Loss of taste or smell | 11.25 (6.28–20.13)                     | 2.62 (1.36–5.05)                   | 2.05 (1.83–2.31)                     |
| Chest Pain         | 1.07 (0.27–4.31)                       | 0.71 (0.1–5.12)                    | 0.77 (0.5–1.2)                       |
| Sore throat        | 0.85 (0.47–1.55)                       | 1.09 (0.86–1.38)                   | 0.79 (0.67–0.91)                     |
| Rhinorrhea         | 0.92 (0.52–1.63)                       | 0.83 (0.53–1.32)                   | 0.93 (0.75–1.17)                     |
| Fever              | 0.84 (0.6–1.18)                        | 1.18 (0.94–1.49)                   | 1.2 (1.1–1.3)                        |
| Cough              | 0.97 (0.81–1.16)                       | 0.93 (0.79–1.11)                   | 0.88 (0.84–0.93)                     |

Abbreviations: GI, gastrointestinal symptoms (i.e. abdominal pain, vomiting or diarrhoea); LR, positive likelihood ratio.

LR values are highlighted in bold when statistically significant.

* Suspected exposure in the survey was defined as a close contact with a confirmed COVID-19 patient or recent (<14 days) international travel.

**Fig. 3.** Positive likelihood ratios for surveyed factors (n = 24 362). Factors are shown on a logarithmic scale with 95% CI, those positively associated with COVID-19 are reports of suspected exposure (see text for definition), fever >37.5°C, and loss of smell or taste. LR, likelihood ratio. Error bars represent 95% CI.
vector [8,17,18]. Given the mandatory duty to serve in the IDF, the included population is highly representative of young Israeli adults and can be generalized to young adults worldwide. Additional strengths are the systemic data collection and measurement throughout the study period and the consistency of laboratory examinations performed in the same protocol, facility and by the same staff. In addition, the free access to health services in the military is of importance in the light of evidence linking socioeconomic and racial disparities to COVID-19 morbidity and mortality [28]. A major shortcoming of this study is the use of self-reported symptoms, which is subject to response bias, especially when the presence of certain symptoms serves as the gatekeeper for PCR approval. In addition, risk for selection bias exists secondary to testing policy, which could underestimate the predictive value of symptoms that do not mandate a swab test. Furthermore, the group of excluded individuals without questionnaire data might bias the results despite being non-differential in origin and with similar characteristics overall. Also, because of the limitations of the SARS-CoV-2 rRT-PCR test, both false-negative and false-positive results could be included; however, PCR remains the reference standard for diagnosis. Finally, secondary to questionnaire phrasing, loss of taste and loss of smell are combined to a single symptom, so we could not appreciate the individual effect of report of either symptom.

In conclusion, reporting of loss of taste or smell, suspicious exposure and fever were strongly associated with a positive SARS-CoV-2 test in a population of predominantly young and healthy adults. We recommend using these self-reported symptoms to streamline testing in this population.

Transparency declaration
The authors declare that they have no conflicts of interest.
Funding: None received.

Author contributions
AF and MN were responsible for the conceptualization of the study. AF, MN and BT were responsible for the methodology and the investigation. ED performed the formal analysis, AF, RY, IT and MN curated the data. The original draft was written by MN, and it was reviewed and edited by MN, BT, IK, GG, GT, BG, EA and NF. Visualisation was by MN, AF and GT. The study was supervised by AF, GT, NF, BG and EA, and project administration was by AF.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2020.12.028.

References
[1] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020;92:401–2.
[2] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. Geneva: WHO Dir Gen Speeches; 2020. 4.
[3] World Health Organization. WHO coronavirus disease dashboard. Geneva: WHO; 2020.
[4] Edlin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA 2020;26:771–83.
[5] Pérè H, Pére H, Pérè H, Podglajen I, Podglajen I, Wack M, et al. Nasal swab sampling for SARS-CoV-2: a convenient alternative in times of nasopharyngeal swab shortage. J Clin Microbiol 2020;58. https://doi.org/10.1128/JCM.00721-20.
[6] Beete C, Skrhavina V, Förster TM, Gaber H, Paul JJ, Curado F, et al. Rapid large-scale COVID-19 testing during shortages. Diagnostics (Basel, Switzerland), vol. 10, no. 4, 2020. https://doi.org/10.3390/diagnostics10040464. Available from:
[7] Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes 2020. Available from: https://doi.org/10.14309/jag.0000000000006642; 2020.
[8] Gandhi M, Yoke DS, Hadvil DV. Asymptomatic transmission, the achilles’ heel of current strategies to control Covid-19. N Engl J Med 2020;382:2158–60.
[9] Xie J, Tong Z, Guan X, Du B, Qiu H, Shatsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med 2020;46:837–40.
[10] Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy. JAMA 2020;323:1545.
[11] Shoer S, Karady T, Keshet A, Shilo S, Rossman H, Gavriel A, et al. Who should we test for COVID-19? A triage model built from national symptom surveys. MedRxiv 2020. 2020.05.18.20105569.
[12] Tostmann A, Bradley J, Bousseaune T, Yiek W-K, Holwerda M, Bleecker-Rovers C, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Eurosurveillance 2020;25:2000508.
[13] Menus C, Valdes AM, Frendin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020;26:1037–40.
[14] Salvatore PP, Sula E, Coyle JP, PhD, Caruso E, Smith AR, et al. Recent increase in COVID-19 cases reported among adults aged 16–22 years — United States, May 31—September 5, 2020. MMWR Mortal Weekly Rep 2020;69:1419–24.
[15] Simchoni M, Kleopstoch I, Fururer A. COVID-19 among young adults. J Isr Mil Med 2020;17:11–5.
[16] KS of Epidemiology. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020;35. https://doi.org/10.3346/jkms.2020.35.e112.
[17] Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. n.d. https://doi.org/10.1384/141591-020-0883-7; 2020.
[18] Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 2020. https://doi.org/10.1016/j.jmii.2020.05.001.
[19] Furur A, Afock A, Sommer A, Keinan-Boker I, Derazne E, Levi Z, et al. Adolescent obesity and middle cancer risk: a population-based cohort study of 2.3 million adolescents in Israel. Lancet Diabetes Endocrinol 2020;8:216–25.
[20] CDC. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic assay for emergency use only. Atlanta, GA: CDC; 2020.
[21] Moore NM, Li H, Schejbal D, Lindley J, Hayden MK. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of sars-cov-2. J Clin Microbiol 2020;58. https://doi.org/10.1128/JCM.00938-20.
[22] Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763–70.
[23] Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209–12.
[24] Home Page. Ministry of health. n.d. Available from: www.health.gov.il/ncov/cases-updates/testing-in-us.html. [Accessed 21 August 2020].
[25] Whittington AM. Coronavirus: rolling out community testing for COVID-19 in the NHS. BMJ 2020. n.d. Available from: blogs.bmj.com/bmj/2020/02/17/coronavirus-rolling-out-community-testing-for-covid-19-in-the-nhs/. [Accessed 21 August 2020].
[26] Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manzo S, Fabiani M, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. MedRxiv 2020;2020.04.08.20056851.
[27] Wiersinga WJ, Rhodes A, Cheng AC, Poock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782–93.
[28] Lucy TJ, Beneke DM. Terrorism and weapons of mass destruction: managing the behavioral reaction in primary care. South Med J 2003;96:394–400.
[29] Salmon Ceron D, Barthes S, Hautefort C, Nguyen Y, Nevoux J, Hamel AL, et al. Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study. J Infect 2020. https://doi.org/10.1016/j.jinf.2020.07.005.